Adenocarcinoma of esophagogastric junction
Conditions
Interventions
Treatment group:The experimental group began intraperitoneal lavage chemotherapy with loplatin immediately after surgery. 500-1000ml 5% glucose water or distilled water containing loplatin (loplatin c
Control group:In the control group, the operation was performed according to the conventional procedure. After abdominal cavity irrigation was completed, the incision was closed to complete the operat
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age 18 ~ 80 years old, gender is not limited. 2) ECOG PS score of physical strength is 0 ~ 1. 3) Patients with Siewert type II adenocarcinoma of the esophagogastric junction confirmed by histopathology will undergo radical esophagogastric junction adenocarcinoma. 4) Patients who had received neoadjuvant therapy and had clinical stage T3-4aN0 or any TN+ in preoperative imaging examination. 5) No retroperitoneal lymph node metastasis was detected by preoperative imaging examination. 6) No distant metastasis were detected by preoperative imaging examination. 7) Women of childbearing age need to take effective contraceptive measures. 8) Can understand the situation of this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) History of other malignant tumors within 5 years. 2) No neoadjuvant therapy was received before surgery. 3) Any presence of M1 was found during the operation. 4) Significant organ failure or other critical disease, including clinically relevant coronary artery disease, cardiovascular disease, or myocardial infarction within 12 months prior to enrollment; A history of severe neurological or psychiatric illness; Severe infection; Active disseminated intravascular coagulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative abdominal metastasis (including peritoneal implantation metastasis and abdominal and pelvic lymph node metastasis); | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence-free survival;1 -, 2 -, and 3-year survival rates;Liver metastasis rate;Safety;Postoperative complications (postoperative bleeding, anastomotic fistula, incision infection, abdominal infection, etc.) occurred in both groups; | — |
Countries
China
Contacts
Public ContactYong Li
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed